SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Merck Sharp & Dohme Corp. – ‘10-K’ for 12/31/05 – ‘EX-31.2’

On:  Monday, 3/13/06, at 4:10pm ET   ·   For:  12/31/05   ·   Private-to-Public:  Document/Exhibit  –  Release Delayed   ·   Accession #:  950123-6-3031   ·   File #:  1-03305

Previous ‘10-K’:  ‘10-K’ on 3/11/05 for 12/31/04   ·   Next:  ‘10-K’ on 2/28/07 for 12/31/06   ·   Latest:  ‘10-K’ on 3/30/10 for 12/31/09   ·   2 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/13/06  Merck Sharp & Dohme Corp.         10-K12/31/05   11:1.1M                                   Donnelley … Solutions/FA

Annual Report   —   Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    368K 
11: COVER     ¶ Comment-Response or Cover Letter to the SEC         HTML      2K 
 3: EX-13       Ex-13: Portions of 2005 Annual Report to            HTML    620K 
                          Stockholders                                           
 4: EX-21       Ex-21: Subsidiaries of Merck & Co., Inc.            HTML     45K 
 5: EX-24.1     Ex-24.1: Power of Attorney                          HTML     16K 
 6: EX-24.2     Ex-24.2: Certified Resolution of Board of           HTML     10K 
                          Directors                                              
 2: EX-12       Ex-12: Computation of Ratios of Earnings to Fixed   HTML     19K 
                          Charges                                                
 7: EX-31.1     Ex-31.1: Certification                              HTML     12K 
 8: EX-31.2     Ex-31.2: Certification                              HTML     12K 
 9: EX-32.1     Ex-32.1: Certification                              HTML      8K 
10: EX-32.2     Ex-32.2: Certification                              HTML      8K 


‘EX-31.2’   —   Ex-31.2: Certification


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  exv31w2  

 

Exhibit 31.2
CERTIFICATION
     I, Judy C. Lewent, certify that:
     1.      I have reviewed this annual report on Form 10-K of Merck & Co., Inc.;
     2.      Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     3.      Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     4.      The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
        a)      Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
        b)      Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
        c)      Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
        d)      Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
     5.      The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
        a)      All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
        b)      Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: March 13, 2006
         
     
  By:   /s/ Judy C. Lewent    
    Judy C. Lewent   
    Executive Vice President & Chief Financial Officer   
 

 


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:3/13/06
For Period End:12/31/0511-K,  ARS
 List all Filings 


2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/04/06  SEC                               UPLOAD10/13/17    1:15K  Merck Sharp & Dohme Corp.
10/04/06  SEC                               UPLOAD10/13/17    1:35K  Merck Sharp & Dohme Corp.
Top
Filing Submission 0000950123-06-003031   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Thu., May 16, 8:15:10.1pm ET